Microsoft demonstrates how to validate database-backed AI applications locally and in CI using the Cosmos DB Emulator.
"Mi insegni?", "Mi fai vedere come si fa?”, “Lo facciamo insieme?". Quante volte un nonno o una nonna si sentono rivolgere queste domande. È il bello di essere dei tutorial in carne e ossa con ...
We seem to have reached peak “get off my lawn” culture, with men having temper tantrums all over the damn place. Whether they’re typing shrill all-caps messages, foaming at the mouth with road rage or ...
Conclusion: Data from this China real-world study show that FUCASO delivers deep and durable responses together with a favorable safety profile in heavily pretreated, high-risk patients with ...
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting ...
--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a ...
— Poster presentation selected for the poster discussion session (Abstract No.: PA-200): in a first-in-human study in 9 heavily pretreated, high-risk patients with relapsed/refractory multiple myeloma ...
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First ...
MRD negativity at 10⁻⁶ independently correlated with prolonged PFS in GEM2014MAIN, enabling treatment discontinuation after 2 years for sustained MRD-negative patients with excellent 7-year landmark ...
Mezigdomide plus elranatamab achieved a 100% ORR and a 92.3% CR or better rate in evaluable anti-BCMA–naive R/R MM, with MRD negativity in 87.5% of assess patients with stringent CRs. Toxicity with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results